Developer docs
API playgroundTry for free, no card

Search company profiles

Resistell AG

Full company profile

uuid0000rg8

Namestring
Resistell AG
Legal namestring
Resistell AG
Websiteurl
resistell.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Resistell AG is a privately held Swiss diagnostics company founded in 2018 as an EPFL spin-off, headquartered in Muttenz near Basel. The company develops a nanomotion-based antibiotic susceptibility testing (AST) platform that detects bacterial viability and antibiotic response by measuring nanoscale vibrations of living cells via micro-mechanical cantilever sensors, combined with proprietary machine learning classification models. This growth-independent phenotypic approach delivers AST results in approximately one hour, versus one to five days for conventional culture-based methods, enabling same-day targeted antibiotic therapy decisions for critically ill patients.

The company operates a dual-product architecture. Phenotech Multistar is the clinical IVD platform delivering 1-hour results with a modular design for simultaneous analysis of up to 12 patient samples, targeting hospital microbiology laboratories across Europe (CE-IVD certified). Phenotech Research is a research-use platform extending the same core technology into broader cellular analysis applications including viable but non-culturable cells, persister cells, tuberculosis, phage therapy, cancer cell analysis, and antifungal testing. Both products are anchored by a peer-reviewed Nature Communications publication (March 2024) demonstrating 90.5-100% training accuracy and 89.5-98.9% independent-test accuracy across antibiotic classes.

Commercially, Resistell is in a pre-launch scaling phase with a sales-led direct enterprise model targeting hospital laboratory directors and infectious disease specialists. The company has executed an international multisite clinical study (PHENOTECH-1) across Switzerland, Spain, and Austria with leading university hospital partners, raised a CHF 8.5M Series B first tranche in December 2022 from EIC Fund, TRUMPF Venture, OCCIDENT, Zürcher Kantonalbank, and others, secured a €1.54M Eurostars grant in March 2024 for a cystic fibrosis joint development with Cellectric and CHUV, and earned three consecutive TOP 10 Swiss Startup awards (2021-2023). Pricing is not publicly disclosed and no commercial revenue has been reported.

Short descriptiontext

Resistell AG is a Swiss EPFL spin-off developing nanomotion-based antibiotic susceptibility testing platforms that deliver phenotypic AST results in approximately one hour, serving hospital microbiology laboratories across Europe with CE-IVD certified clinical and research-use products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMuttenz, Switzerland
HQ citystring
Muttenz
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibiotic susceptibility testing, nanomotion diagnostic devices, phenotypic AST platform, rapid antimicrobial detection, in-vitro diagnostics
Industry3 codes
PRIMARYHLAJAIAF
Antimicrobial Resistance (AMR) & Antibiotic Susceptibility Reference Networks
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks
SECONDARYHLAGADAE
Microbiology & Sterility Assurance (Bioburden/Endotoxin/Sterility)
SECONDARYHLAGAEAF
Microbiology & Infectious Disease Testing (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
In-Vitro Diagnostics (Clinical Microbiology)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Phenotech Multistar
Description

Ultra-rapid Antibiotic Susceptibility Testing (AST) Platform delivering results in 1 hour, using nanomotion technology for phenotypic testing independent of bacterial growth.

resistell.com
+1 more record
Core offering1 text field

Resistell AG develops and sells diagnostic instruments that perform antibiotic susceptibility testing (AST) by detecting nanomotion (nanoscale vibrations) of living bacterial cells exposed to antibiotics, using proprietary cantilever sensors combined with machine learning classifiers. Its flagship Phenotech Multistar instrument delivers AST results in approximately 1 hour for up to 12 patient samples simultaneously, compared to 1–5 days for conventional growth-based methods, and is targeted at hospital microbiology laboratories for guiding targeted antibiotic therapy in critically ill patients with bloodstream infections.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Results delivered in approximately 1 hour vs. 1-5 days for conventional methods
+2 more records
Product overview1 text field

Resistell AG offers a dual-product platform architecture based on proprietary nanomotion technology for antibiotic susceptibility testing (AST). The core offering consists of two products: Phenotech Multistar (commercial clinical product delivering results in 1 hour for bloodstream infections) and Phenotech Research (R&D/research version for broader cellular analysis applications). Both products share the same underlying nanomotion detection technology platform using micro-mechanical cantilever sensors to measure bacterial vibrations and machine learning classification software for phenotypic analysis.

Product and service2 records
1Phenotech Multistar
CategoryClinical diagnostic instrument (in-vitro diagnostics)
Description

Ultra-rapid antibiotic susceptibility testing (AST) instrument for hospital diagnostic laboratories. Detects nanomotion of living bacterial cells exposed to antibiotics using cantilever sensors and machine learning classification, delivering phenotypic AST results in exactly 1 hour independent of bacterial growth. Modular design supports simultaneous analysis of up to 12 patient samples and is compatible with routine diagnostic laboratory workflows for bloodstream and other serious bacterial infections.

2Phenotech Research
CategoryResearch-use instrument (cellular analysis)
Description

Research-use platform for nanoscale cellular vibration analysis independent of growth or reporter systems. Enables study of previously inaccessible growth phenotypes including viable but non-culturable (VBNC) cells and persister cells, with applications in tuberculosis, phage therapy, cancer cell analysis, and antifungal susceptibility testing. Targeted at academic, translational, and industrial research laboratories.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-04
Description

Joint Eurostars project partnership to build Phenotech-CF, a rapid antibiotic susceptibility testing platform combining both companies' technologies for improved detection capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-27
Description

Partnership for macozinone development, evaluating Resistell's rapid AST technology for susceptibility testing of this novel anti-tuberculosis compound.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical study partner collaborating on Eurostars project for validation and clinical evaluation of rapid AST technology in hospital setting.

4University Hospital Ramón y Cajal
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical study partner conducting validation studies of antibiotic susceptibility testing technology in Madrid, Spain.

5Medical University of Innsbruck
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical study partner conducting validation studies of antibiotic susceptibility testing technology in Austria.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based commercial-stage rapid phenotypic AST company (Accelerate Pheno system) delivering results in approximately 7 hours for bloodstream infections. Closest direct competitor to Resistell in rapid phenotypic AST for hospital microbiology labs.

TypeBroad incumbent
Description

Global leader in clinical microbiology with Vitek 2 AST system and Vitek MS MALDI-TOF identification platform. Incumbent supplier to most hospital microbiology labs and the principal workflow that Resistell must displace or augment.

TypeBroad incumbent
Description

Major incumbent in hospital microbiology through the BD Phoenix M50 AST system and BD MAX molecular platform. Competes broadly with Resistell for the routine AST workflow slot in hospital labs.

TypeDirect peer
Description

Swedish diagnostics company developing the ASTar system for rapid phenotypic AST using a proprietary microfluidic single-cell approach. Targets the same 1-hour-class rapid AST category in hospital bloodstream infection workflows.

TypeDirect peer
Description

Boston-based rapid phenotypic AST developer with Next Generation Phenotyping (NGP) platform targeting same-day results for bloodstream infections. Competes head-to-head with Resistell in the rapid AST category.

TypeDirect peer
Description

Developer of the Reveal rapid AST system using proprietary volatile organic compound sensing for growth-based phenotypic AST in hours. Direct competitor in the rapid AST hospital segment.

TypeEmerging player
Description

Early-stage rapid AST company applying machine learning and single-cell morphology to bacterial phenotypic AST, overlapping with Resistell's ML-based phenotypic approach. Emerging competitor in the same category.

TypeBroad incumbent
Description

Major diagnostic instrumentation company with MALDI Biotyper for bacterial ID and is developing rapid AST solutions (e.g., MBT ASTar). Operates broadly in clinical microbiology with overlapping capabilities.

TypeEmerging player
Description

Developer of T2 Magnetic Resonance-based rapid diagnostics for bloodstream infections (T2Bacteria, T2Candida). Adjacent in rapid phenotypic-style detection of sepsis-causing pathogens but with a different technology modality.

10Cellectric
TypeOthers
Description

Swedish sample-preparation technology company that is a Resistell co-development partner in the Eurostars Phenotech-CF project. Comparable as an adjacent enabling technology provider in the rapid AST workflow for cystic fibrosis samples.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Resistell AG

In-Vitro Diagnostics (Clinical Microbiology)resistell.com

Resistell AG is a Swiss EPFL spin-off developing nanomotion-based antibiotic susceptibility testing platforms that deliver phenotypic AST results in approximately one hour, serving hospital microbiology laboratories across Europe with CE-IVD certified clinical and research-use products.

What Resistell AG does

Resistell AG is a privately held Swiss diagnostics company founded in 2018 as an EPFL spin-off, headquartered in Muttenz near Basel. The company develops a nanomotion-based antibiotic susceptibility testing (AST) platform that detects bacterial viability and antibiotic response by measuring nanoscale vibrations of living cells via micro-mechanical cantilever sensors, combined with proprietary machine learning classification models. This growth-independent phenotypic approach delivers AST results in approximately one hour, versus one to five days for conventional culture-based methods, enabling same-day targeted antibiotic therapy decisions for critically ill patients.

The company operates a dual-product architecture. Phenotech Multistar is the clinical IVD platform delivering 1-hour results with a modular design for simultaneous analysis of up to 12 patient samples, targeting hospital microbiology laboratories across Europe (CE-IVD certified). Phenotech Research is a research-use platform extending the same core technology into broader cellular analysis applications including viable but non-culturable cells, persister cells, tuberculosis, phage therapy, cancer cell analysis, and antifungal testing. Both products are anchored by a peer-reviewed Nature Communications publication (March 2024) demonstrating 90.5-100% training accuracy and 89.5-98.9% independent-test accuracy across antibiotic classes.

Commercially, Resistell is in a pre-launch scaling phase with a sales-led direct enterprise model targeting hospital laboratory directors and infectious disease specialists. The company has executed an international multisite clinical study (PHENOTECH-1) across Switzerland, Spain, and Austria with leading university hospital partners, raised a CHF 8.5M Series B first tranche in December 2022 from EIC Fund, TRUMPF Venture, OCCIDENT, Zürcher Kantonalbank, and others, secured a €1.54M Eurostars grant in March 2024 for a cystic fibrosis joint development with Cellectric and CHUV, and earned three consecutive TOP 10 Swiss Startup awards (2021-2023). Pricing is not publicly disclosed and no commercial revenue has been reported.

Resistell AG firmographics

Firmographics
Name
Resistell AG
Legal name
Resistell AG
Website
https://resistell.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Resistell AG is a Swiss EPFL spin-off developing nanomotion-based antibiotic susceptibility testing platforms that deliver phenotypic AST results in approximately one hour, serving hospital microbiology laboratories across Europe with CE-IVD certified clinical and research-use products.
Ownership category
akta.pro rank

Resistell AG industry classification

Industry
Product category
In-Vitro Diagnostics (Clinical Microbiology)
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAJAIAF
Antimicrobial Resistance (AMR) & Antibiotic Susceptibility Reference Networks
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks
SECONDARYHLAGADAE
Microbiology & Sterility Assurance (Bioburden/Endotoxin/Sterility)
SECONDARYHLAGAEAF
Microbiology & Infectious Disease Testing (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Antibiotic susceptibility testing
  • Nanomotion diagnostic devices
  • Phenotypic AST platform
  • Rapid antimicrobial detection
  • In-vitro diagnostics

Where Resistell AG is headquartered

Location

Headquarters

HQ city
Muttenz
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Resistell AG business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Resistell AG product offering

Product offering

Core offering

Resistell AG develops and sells diagnostic instruments that perform antibiotic susceptibility testing (AST) by detecting nanomotion (nanoscale vibrations) of living bacterial cells exposed to antibiotics, using proprietary cantilever sensors combined with machine learning classifiers. Its flagship Phenotech Multistar instrument delivers AST results in approximately 1 hour for up to 12 patient samples simultaneously, compared to 1–5 days for conventional growth-based methods, and is targeted at hospital microbiology laboratories for guiding targeted antibiotic therapy in critically ill patients with bloodstream infections.

Product overview

Resistell AG offers a dual-product platform architecture based on proprietary nanomotion technology for antibiotic susceptibility testing (AST). The core offering consists of two products: Phenotech Multistar (commercial clinical product delivering results in 1 hour for bloodstream infections) and Phenotech Research (R&D/research version for broader cellular analysis applications). Both products share the same underlying nanomotion detection technology platform using micro-mechanical cantilever sensors to measure bacterial vibrations and machine learning classification software for phenotypic analysis.

Differentiator

Problem solved

Functional benefit

Brands

  • Phenotech Multistar: Ultra-rapid Antibiotic Susceptibility Testing (AST) Platform delivering results in 1 hour, using nanomotion technology for phenotypic testing independent of bacterial growth.
  • Phenotech Research

Products and services

  • Phenotech Multistar Ultra-rapid antibiotic susceptibility testing (AST) instrument for hospital diagnostic laboratories. Detects nanomotion of living bacterial cells exposed to antibiotics using cantilever sensors and machine learning classification, delivering phenotypic AST results in exactly 1 hour independent of bacterial growth. Modular design supports simultaneous analysis of up to 12 patient samples and is compatible with routine diagnostic laboratory workflows for bloodstream and other serious bacterial infections.
  • Phenotech Research Research-use platform for nanoscale cellular vibration analysis independent of growth or reporter systems. Enables study of previously inaccessible growth phenotypes including viable but non-culturable (VBNC) cells and persister cells, with applications in tuberculosis, phage therapy, cancer cell analysis, and antifungal susceptibility testing. Targeted at academic, translational, and industrial research laboratories.

Quantifiable outcome

  • Results delivered in approximately 1 hour vs. 1-5 days for conventional methods
  • +2 more outcomes

Companies that use Resistell AG

Customer profile

Named customers3 records

Segments1 record

Ideal customer profiles2 records

Resistell AG technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Resistell AG partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • CellectriccoreStrategic or Co-development Partner · 4 March 2024Joint Eurostars project partnership to build Phenotech-CF, a rapid antibiotic susceptibility testing platform combining both companies' technologies for improved detection capabilities.
  • iM4TBcoreStrategic or Co-development Partner · 27 March 2023Partnership for macozinone development, evaluating Resistell's rapid AST technology for susceptibility testing of this novel anti-tuberculosis compound.
  • Lausanne University Hospital (CHUV)coreStrategic or Co-development PartnerClinical study partner collaborating on Eurostars project for validation and clinical evaluation of rapid AST technology in hospital setting.
  • University Hospital Ramón y CajalcoreStrategic or Co-development PartnerClinical study partner conducting validation studies of antibiotic susceptibility testing technology in Madrid, Spain.
  • Medical University of InnsbruckcoreStrategic or Co-development PartnerClinical study partner conducting validation studies of antibiotic susceptibility testing technology in Austria.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Resistell AG competitors and assessment

Company assessment

Direct peers

  • Accelerate Diagnostics: US-based commercial-stage rapid phenotypic AST company (Accelerate Pheno system) delivering results in approximately 7 hours for bloodstream infections. Closest direct competitor to Resistell in rapid phenotypic AST for hospital microbiology labs.
  • Q-linea: Swedish diagnostics company developing the ASTar system for rapid phenotypic AST using a proprietary microfluidic single-cell approach. Targets the same 1-hour-class rapid AST category in hospital bloodstream infection workflows.
  • Selux Diagnostics: Boston-based rapid phenotypic AST developer with Next Generation Phenotyping (NGP) platform targeting same-day results for bloodstream infections. Competes head-to-head with Resistell in the rapid AST category.
  • Specific Diagnostics: Developer of the Reveal rapid AST system using proprietary volatile organic compound sensing for growth-based phenotypic AST in hours. Direct competitor in the rapid AST hospital segment.

Broad incumbents

  • bioMérieux: Global leader in clinical microbiology with Vitek 2 AST system and Vitek MS MALDI-TOF identification platform. Incumbent supplier to most hospital microbiology labs and the principal workflow that Resistell must displace or augment.
  • BD (Becton Dickinson): Major incumbent in hospital microbiology through the BD Phoenix M50 AST system and BD MAX molecular platform. Competes broadly with Resistell for the routine AST workflow slot in hospital labs.
  • Bruker: Major diagnostic instrumentation company with MALDI Biotyper for bacterial ID and is developing rapid AST solutions (e.g., MBT ASTar). Operates broadly in clinical microbiology with overlapping capabilities.

Emerging players

  • Pattern Bioscience: Early-stage rapid AST company applying machine learning and single-cell morphology to bacterial phenotypic AST, overlapping with Resistell's ML-based phenotypic approach. Emerging competitor in the same category.
  • T2 Biosystems: Developer of T2 Magnetic Resonance-based rapid diagnostics for bloodstream infections (T2Bacteria, T2Candida). Adjacent in rapid phenotypic-style detection of sepsis-causing pathogens but with a different technology modality.

Others

  • Cellectric: Swedish sample-preparation technology company that is a Resistell co-development partner in the Eurostars Phenotech-CF project. Comparable as an adjacent enabling technology provider in the rapid AST workflow for cystic fibrosis samples.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Resistell AG social profiles

Digital presence

Resistell AG financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Resistell AG leadership team

Management profile

Number of profiles

Profiles12 records

Resistell AG funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Resistell AG M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Resistell AG

What does Resistell AG do?

Resistell AG develops and sells diagnostic instruments that perform antibiotic susceptibility testing (AST) by detecting nanomotion (nanoscale vibrations) of living bacterial cells exposed to antibiotics, using proprietary cantilever sensors combined with machine learning classifiers. Its flagship Phenotech Multistar instrument delivers AST results in approximately 1 hour for up to 12 patient samples simultaneously, compared to 1–5 days for conventional growth-based methods, and is targeted at hospital microbiology laboratories for guiding targeted antibiotic therapy in critically ill patients with bloodstream infections.

Is Resistell AG a public or private company?

Resistell AG is a private company. It is classified as venture growth investor backed and is currently operating.

When was Resistell AG founded?

Resistell AG was founded in 2018. It employs 11 to 50 people.

Where is Resistell AG based?

Resistell AG is headquartered in Muttenz, Switzerland, in the Europe region.

Who are Resistell AG's main competitors?

Direct peers on record are Accelerate Diagnostics, Q-linea, Selux Diagnostics and Specific Diagnostics. Broad incumbents are bioMérieux, BD (Becton Dickinson) and Bruker. Emerging players are Pattern Bioscience and T2 Biosystems. Cellectric is listed as an others.

Does Resistell AG have an API?

No public API is recorded for Resistell AG.

What industry is Resistell AG in?

Resistell AG's product category is In-Vitro Diagnostics (Clinical Microbiology). Its primary akta.pro industry code is HLAJAIAF, Antimicrobial Resistance (AMR) & Antibiotic Susceptibility Reference Networks, with a secondary code of HLAGADAE, Microbiology & Sterility Assurance (Bioburden/Endotoxin/Sterility). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NatureNanomotion technology for ultrarapid antibiotic susceptibility testing and performance evaluationResistell AG is developing nanomotion-based technology for rapid antibiotic susceptibility testing, using cellular vibrations and machine learning to assess antimicrobial efficacy. The platform is being evaluated for bacteraemia/sepsis and M. tuberculosis, and may extend to fungi, cancer, and phage therapeutics.startupticker.chInnovative Medicines for Tuberculosis relies on Resistell’s technologyResistell partnered with the iM4TB foundation to deploy its Phenotech device for testing macozinone, a TB drug candidate. The device generates phenotypic data ten times faster than conventional methods, accelerating development. Macozinone is now undergoing formulation for phase 2 trials.BioAlpsResistell AG closes its series B first tranche of CHF 8.5 MillionResistell AG has closed the first tranche of its Series B financing round, raising CHF 8.5 million from investors including EIC Fund and TRUMPF Venture. The capital will fund clinical trials for antibiotic susceptibility testing and the market entry of its Phenotech Research device to combat antimicrobial resistance. Resistell aims to complete the full Series B in 2023 while seeking IVDR certification and commercial partnerships.BitlyResistell raises CHF8.5 million to bring its first product to the marketResistell AG has closed the first tranche of its Series B financing round, raising CHF 8.5 million from investors including EIC Fund and TRUMPF Venture to support clinical trials and market entry for its Phenotech Research device. The funding will facilitate IVDR certification and commercialization efforts for a diagnostic tool that reduces antibiotic susceptibility testing time from days to hours. Resistell is currently conducting clinical studies at the University Hospital in Lausanne and other European hospitals to validate the technology's accuracy against gold standard methods.VenturelabResistell raises CHF 8.5 million to complete clinical trials for antibiotic susceptibility testing: interview with CEO Danuta CichockaResistell AG has closed the first tranche of its Series B financing round, raising CHF 8.5 million from investors including EIC Fund and TRUMPF Venture to complete clinical trials for its antibiotic susceptibility testing device. The company is simultaneously advancing a second multi-site study across three European hospitals while preparing for IVDR certification and market entry of its Phenotech Research device. This funding secures Resistell's ability to navigate regulatory pathways and commercialize its nanomotion technology platform despite current economic instability.startupticker.chPfizer backs medtech startup ResistellResistell, an EPFL spinoff founded in 2018 that develops a rapid antibiotic susceptibility test based on nano-scale cell vibrations, has launched a research project funded by an independent grant from Pfizer. The project will assess the startup's Phenotech device, which delivers AST results for Gram-negative bacteria in as little as four hours, for a novel antibiotic.ResistellResistell initiates a research project funded by an independent grant from Pfizer AGResistell, a Swiss start-up focused on speeding antibiotic resistance diagnostics, announced it has launched a research project to evaluate the applicability of its antibiotic susceptibility test to a novel antibiotic. The project is funded by an independent grant from Pfizer AG. No further details on the grant amount, the antibiotic, or the project timeline were disclosed.startupticker.chResistell enters clinical studiesResistell AG launched its Performance Evaluation Study of its nanomotion-based antibiotic susceptibility test at Lausanne University Hospital, with HEMEX collaborating. The study aims to validate the rapid diagnostic, which reduces time to results from days to hours, over 12 months. The company seeks clinical evidence to bring the technology to market.